Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial

Nature Clinical Practice. Cardiovascular Medicine
Helmut DrexlerKai C Wollert

Abstract

Emerging evidence suggests that bone-marrow-derived stem and progenitor cells can be used to improve cardiac function after acute myocardial infarction. We tested this concept in the randomized, controlled, BOOST (bone marrow transfer to enhance ST-elevation infarct regeneration) clinical trial. Following successful percutaneous coronary intervention for acute ST-elevation myocardial infarction, patients received an intracoronary transfer of autologous bone marrow cells (BMCs). After 6 months, global left ventricular ejection fraction, as determined by magnetic resonance imaging, was significantly improved in the BMC-treated group compared with the control group. BMC transfer enhanced left ventricular systolic function, primarily in myocardial segments adjacent to the infarcted area, and also had a positive effect on diastolic function. BMC transfer did not increase the risk of adverse clinical events and did not promote in-stent re-stenosis or proarrhythmic effects. In principle, the effects of BMC transfer on ejection fraction were sustained at 18-month follow-up. Notably, radioactive labeling of BMCs and positron emission tomography showed that these beneficial effects are achieved with limited cardiac homing of BMCs after i...Continue Reading

Associated Clinical Trials

Citations

Sep 1, 2008·Journal of Cardiovascular Translational Research·Alexander R LyonNicholas S Peters
Oct 5, 2007·Annual Review of Medicine·Benjamin D Humphreys, Joseph V Bonventre
Jul 17, 2008·Biological Chemistry·Alicia Rovó, Alois Gratwohl
Jan 31, 2012·Imaging in Medicine·Yingli FuDara L Kraitchman
Apr 9, 2008·Journal of Molecular and Cellular Cardiology·Victoria L T Ballard, Jay M Edelberg
Jun 4, 2010·Journal of Cellular and Molecular Medicine·Cristiano SpadaccioJorge A Genovese
Mar 24, 2012·Journal of Surgical Oncology·Philip S MullenixEdmund P Alexander
Nov 22, 2007·Expert Opinion on Therapeutic Targets·Victoria L T Ballard, Jay M Edelberg
Apr 28, 2007·Cytotherapy·I McNiece
Nov 26, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Sunil RangappaJames Forrester
Dec 5, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Sheik WiselPeriannan Kuppusamy
Jul 31, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Mahmood KhanPeriannan Kuppusamy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.